Rahul Aras, Ph.D.
(President and Chief Executive Officer) is the founding CEO for Juventas Therapeutics. Dr. Aras has led the Company since its inception in 2007 and has leveraged his scientific research and business experience to lead Juventas towards commercialization of its innovative therapies. Dr. Aras has successfully raised more than $38 million in venture capital and grant funding to transition Juventas’ technologies from the laboratory into mid-stage clinical trials. Prior to leading Juventas, Dr. Aras was the Director of Life Science Commercialization at Cleveland Clinic Innovations where he managed commercialization of all biotechnology and pharmaceutical related technologies developed at Cleveland Clinic. Dr. Aras has held research positions at Vanderbilt University Medical Center and Massachusetts General Hospital and has published articles in several leading scientific journals. He received a B.S. from Tufts University and a Ph.D. in biomedical research from New York University.
Marc Penn, M.D., Ph.D.
(Founder and Chief Medical Officer)
is the Director of Research at the Summa Cardiovascular Institute in Akron, Ohio and Professor of Medicine and Integrative Medical Sciences at Northeast Ohio Medical University where he leads the Skirball Laboratory for Cardiovascular Cellular Therapeutics. Dr. Penn was a staff cardiologist at the Cleveland Clinic from 2000 – 2011 where he served as the Director of the Coronary Intensive Care Unit, Director of the Experimental Animal Laboratory, Director of the Bakken Heart-Brain Institute, and the first Director of the Center for Cardiovascular Cell Therapy. He is a serial entrepreneur listed on more than 50 patents and patent applications and has contributed to the formation of multiple companies in the device, diagnostic and therapeutic spaces. Dr. Penn completed his undergraduate and postgraduate work at Case Western Reserve University completing a Ph.D. in Biomedical Engineering in 1989 and Doctor of Medicine in 1994.
(Senior Vice President, Finance and Operations)
leads Juventas’ finance and operations functions. Prior to Juventas, Troy worked with Esperion Therapeutics (ESPR) where he served as a member of the executive leadership team in the role of Vice President, Finance and Business Development. While with the company, Troy helped secure nearly $140M in public and private financing and was instrumental in the IPO of the company. Previously, Mr. Ignelzi was the Vice President, Business Development and Strategic Planning at Insys Therapeutics (INSY) where he helped secure $50M in financing and led licensing, business development, strategic planning and operational activities. Troy’s licensing efforts led to the successful negotiation and acquisition of multiple product and drug delivery device candidates including the currently marketed Subsys. He received a BS in Accounting/Finance from Ferris State University.
Joseph Pastore, Ph.D.
(Vice President, Product Development) oversees manufacturing, preclinical, and clinical development. He has led the team that has translated Juventas’ lead product, JVS-100, from concept through Phase II trials. He is responsible for development and implementation of clinical/regulatory strategy, internal staffing and outsourcing of clinical operations, and leading interactions with the FDA which includes the approval of multiple Investigational New Drug (IND) submissions. Previous to Juventas, he worked with Guidant Corporation (acquired by Boston Scientific) where he was responsible for translating novel cardiac therapies from concept to clinic. He managed pre-clinical, first-in-man, and Phase II clinical trials, and worked cross-functionally with business development, marketing, reimbursement, and regulatory teams to build and execute development strategies for early stage products. He received his Ph.D. in Biomedical Engineering from Case Western Reserve University.
Paul Resnick, M.D., M.B.A.
(Vice President, Business Development) leads Juventas' business and commercial development. Prior to Juventas, Dr. Resnick led business development for Intellikine, culminating in its acquisition by Takeda Pharmaceuticals. He previously held roles at Pfizer, Rinat Neuroscience (acquired by Pfizer), InterMune, and Roche and also practiced medicine. Dr. Resnick's professional experience includes product and business development with solid performance leading and executing business strategy resulting in transforming collaborations. Dr. Resnick earned a Master of Business Administration from the Wharton School of the University of Pennsylvania and a Doctor of Medicine from the Medical College of Wisconsin.